<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>18020892</identifier>
<setSpec>0212-7199</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Huanca Mamani, I</dc:author>
<dc:author>Ruiz Domínguez, R</dc:author>
<dc:description xml:lang="en">The Catastrophic Antiphospholipid Syndrome (CAS) results in multiorgan system failure. All patients develop occlusive accident in a short period (days to weeks), with a mortality of 50%. Treatment can include glucocorticoids, heparin, plasmatic exchange, ciclofosfamide and intravenous globulin. The present article treat of female patient lairs Systemic Eritematous Lupus (SLE), anticardiolipine antibodies, anti ribonucleoprotein antibodies (antiRNP) and multiorgan systemic failure, she survived thanks to the multidisciplinary a early treatment.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:date>2007 Jul </dc:date>
<dc:title xml:lang="es">Debut de lupus eritematoso sistémico con síndrome antifosfolipídico catastrófico: beneficio del tratamiento precoz.</dc:title>
<dc:title xml:lang="en">[Debut of systemic lupus eritematous with catastrophic antiphospholipid syndrome: benefit of the early treatment].</dc:title>
<dc:publisher>Anales de medicina interna (Madrid, Spain : 1984)</dc:publisher>
</metadata>
</record>
</pubmed-document>
